AUDIENCED

Paramedicine workforce across Australian & New Zealand

Liz Thyer is an Associate Professor in the Western Sydney University Paramedicine program and is passionate about innovations and excellence in health sciences teaching and learning. 

She was an advanced life support paramedic with Ambulance Victoria for 11 years including roles as a clinical instructor and peer support officer. She has previously worked at Victoria University with the Paramedic programs and at Deakin University in Learning Futures. 

New AIDH digital strategy adds pillar to previous aims 

Australasian Institute of Digital Health (AIDH), today has released the AIDH Strategic Plan for 2026–2028, recently approved by the Board. This plan acts as a roadmap, as well as a shared statement of purpose and intent, guiding where AIDH will focus its effort, investment and voice over the next three years.

Intersection of multiple births, birth trauma and perinatal mental health

Mothers of multiples are five times more likely to experience depression and have triple the rates of anxiety compared to mothers of singletons. Danya McStein is a Clinical Team Manager at Gidget Foundation Australia, talks about mothers expecting twins showing prenatal depressive symptoms, while postpartum, facing higher risks of clinical exhaustion and postpartum depression.

Trials in treating STIs, vaccines and lipid lowering medications

Since joining Paratus Clinical Research in 2022, Dr Pi Lip Seet has served as both Principal Investigator and Sub-Investigator across Phase I–IV industry-sponsored clinical trials. His research experience spans vaccines, immunology, cardiovascular and endocrine disease, respiratory medicine, gastroenterology, pain management, sleep medicine and adult psychiatry. He has been involved in multiple vaccine development programs, including RSV, influenza, COVID-19, herpes zoster and pneumococcal studies.

Clinical pain neuroscientist talks about how the brain processes pain information

Persistent pain affects one in five Australians and costs the nation an estimated $73 billion per year in health system costs, lost productivity and other financial costs.

Persistent pain also has debilitating personal costs – negatively impacting quality of life and the ability to engage in meaningful work and life activities.

Despite the enormity of this problem, very few effective treatments exist with most showing only small to moderate improvements. New treatments are desperately needed. The group believes the best way to create impactful change is to work with people with lived experience of persistent pain to devise solutions with them, not for them.

Therapy to prevent hepatocellular carcinoma in people with liver cirrhosis

Professor John Olynyk is a Gastroenterologist & Hepatologist with over 30 years’ experience, primarily at The Fiona Stanley & Fremantle Hospital Group. He planned the Gastroenterology and Hepatology Service for the Fiona Stanley Hospital and was Head Department from 2010 until 2020.

Professor John Olynyk was appointed as Associate Dean and Head of the Medical Discipline at Curtin University in 2023 until 2025 and is now Associate Director, Clinical Engagement, Curtin Medical Research Institute, Curtin University.

Identification & characterisation of molecular drivers of therapeutic resistance

Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.

He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.

Liver cancer & patient-derived tumour organoids

Dr Benjamin Dwyer is a translational cancer researcher driven by a clear purpose: to ensure discoveries made in the laboratory genuinely improve outcomes for patients.

Based at Curtin University, he established and now leads the organoid platform within the Liver Cancer Collaborative and directs the WA Organoid Innovation Hub, working at the intersection of biology, medicine and biotechnology to accelerate new treatments for liver cancer.

Developing upper limb motor biomarkers of dementia

Kaylee is currently a research fellow with the Wicking Dementia Research and Education Centre at the University of Tasmania. She has recently submitted her PhD thesis, reporting the findings of her research on developing upper limb motor biomarkers of dementia. She has postgrad degrees in physiotherapy and experience working in the community and aged care across Tasmania for several years, where she worked with people with dementia.

Metabolic phenotyping, lipidomics & bioinformatics in dementia

Dr Luke Whiley is a dementia researcher whose work focuses on understanding how the body’s metabolism, particularly the biology of fats known as lipids, influences our health throughout ageing.

His research explores how the body responds to illness, lifestyle, and environmental stress at a chemical level, and how these responses shape longterm disease risk. Using advanced blood-based measurement technologies, Dr Whiley studies thousands of small molecules at once to build a snapshot of a person’s metabolic health. By combining these measurements with data science approaches, his work identifies biological pathways that become disrupted in disease, providing insight into why some people are more vulnerable to conditions such as dementia.

Scroll to top